Home > Publications Database > Clinical value of 18 F‐PI2620‐PET in the diagnostic workup of patients with suspected Progressive Supranuclear Palsy > print

001     283042
005     20251230103618.0
024 7 _ |a 10.1002/alz70856_102121
|2 doi
024 7 _ |a 1552-5260
|2 ISSN
024 7 _ |a 1552-5279
|2 ISSN
037 _ _ |a DZNE-2025-01449
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Palleis, Carla
|0 P:(DE-2719)9000852
|b 0
|e First author
111 2 _ |a Alzheimer’s Association International Conference
|g AAIC 25
|c Toronto
|d 2025-07-27 - 2025-07-31
|w Canada
245 _ _ |a Clinical value of 18 F‐PI2620‐PET in the diagnostic workup of patients with suspected Progressive Supranuclear Palsy
260 _ _ |c 2025
336 7 _ |a Abstract
|b abstract
|m abstract
|0 PUB:(DE-HGF)1
|s 1767014588_31207
|2 PUB:(DE-HGF)
336 7 _ |a Conference Paper
|0 33
|2 EndNote
336 7 _ |a INPROCEEDINGS
|2 BibTeX
336 7 _ |a conferenceObject
|2 DRIVER
336 7 _ |a Journal Article
|0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|m journal
336 7 _ |a Output Types/Conference Abstract
|2 DataCite
336 7 _ |a OTHER
|2 ORCID
520 _ _ |a Background:Progressive Supranuclear Palsy (PSP) is a rapidly progressing 4-repeat tauopathy, presenting with clinically heterogeneous phenotypes. Currently, diagnoses are based solely on clinical criteria but reliable diagnostic classification remains particularly challenging at early stages. 18F-PI-2620 tau-PET is an evolving neuroimaging biomarker to capture 4-repeat tau (4RT) deposits in vivo with clear diagnostic potential in research settings. To determine the added clinical value of 18F-PI-2620 tau-PET in the diagnostic workup of PSP, we evaluated whether 18F-PI-2620-assessed 4RT positivity (i.e. using the basal ganglia as a target readout) predicts subsequent increases of diagnostic certainty for PSP, indicative of 4RT pathology driving clinical progression.Method:We collected monocentric longitudinal data at the LMU Hospital in Munich, from a non-randomized prospective cohort study between October 2018 and December 2024. Data collection included pre-PET visits with routine clinical classification following the MDS criteria. In addition, we performed 18F-PI-2620 tau-PET with dichotomous visual read assessments of 4RT pathology by an expert reader and collected clinical follow-up data or autopsy information.Results:342 patients with a pre-PET differential diagnosis of PSP were referred to 18F-PI-2620 tau-PET in clinical routine. Of those, 200 patients (61.5% male, mean±sd age 69.2±8.3 years) had a post-PET clinical follow-up between 12-24 months (mean±sd 17.1±4.2 months). 137 patients (68.5%) were rated 4RT-positive at baseline (Figure 1). The distribution of certainty of PSP diagnosis at baseline and at follow-up is displayed in Figure 2 (A&B: all PSP phenotypes; C&D: PSP-Richardson Syndrome [RS]; E&F: variant PSP subtypes). Change to a non-PSP diagnosis at follow-up occurred in 23.5%, identified by a negative baseline tau-PET in 95.5%. In contrast, 79% of tau-PET-positive patients with suggestive PSP progressed to a higher diagnostic certainty, 3% had histopathological confirmation of PSP diagnosis, 13% remained suggestive PSP, and 5% received a non-PSP diagnosis at follow-up.Conclusion:18F-PI-2620 tau-PET can successfully identify patients that progress along expected 4RT clinical spectra. This supports 18F-PI-2620 tau-PET as a 4RT biomarker, with the potential to facilitate early biomarker-based diagnosis when clinical criteria may still lack sensitivity and specificity. This development can be transformative for clinical decision making, pre-symptomatic identification of PSP and stratifying patients for disease modifying clinical trials.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, Journals: pub.dzne.de
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Supranuclear Palsy, Progressive: diagnostic imaging
|2 MeSH
650 _ 2 |a Supranuclear Palsy, Progressive: diagnosis
|2 MeSH
650 _ 2 |a Supranuclear Palsy, Progressive: metabolism
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a tau Proteins: metabolism
|2 MeSH
650 _ 2 |a Biomarkers: metabolism
|2 MeSH
650 _ 2 |a Positron-Emission Tomography
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Longitudinal Studies
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Disease Progression
|2 MeSH
700 1 _ |a Franzmeier, Nicolai
|b 1
700 1 _ |a Gnoerich, Johannes
|0 P:(DE-2719)9001652
|b 2
700 1 _ |a Jäck, Alexander
|0 P:(DE-2719)9002626
|b 3
700 1 _ |a Bernhardt, Alexander M
|0 P:(DE-2719)9002620
|b 4
700 1 _ |a Katzdobler, Sabrina
|0 P:(DE-2719)9001160
|b 5
700 1 _ |a Fietzek, Urban
|0 P:(DE-2719)9001214
|b 6
700 1 _ |a Weidinger, Endy
|0 P:(DE-2719)9000882
|b 7
700 1 _ |a Frontzkowski, Lukas
|b 8
700 1 _ |a Roemer-Cassiano, Sebastian
|b 9
700 1 _ |a Zwergal, Andreas
|b 10
700 1 _ |a Barthel, Henryk
|b 11
700 1 _ |a Sabri, Osama
|0 P:(DE-2719)2814810
|b 12
700 1 _ |a Levin, Johannes
|0 P:(DE-2719)2811659
|b 13
700 1 _ |a Höglinger, Günter U
|0 P:(DE-2719)2811373
|b 14
700 1 _ |a Brendel, Matthias
|0 P:(DE-2719)9001539
|b 15
|e Last author
773 _ _ |a 10.1002/alz70856_102121
|g Vol. 21, no. S2, p. e102121
|0 PERI:(DE-600)2201940-6
|n S2
|p e102121
|t Alzheimer's and dementia
|v 21
|y 2025
|x 1552-5260
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/283042/files/DZNE-2025-1449.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/283042/files/DZNE-2025-1449.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:283042
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9000852
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 2
|6 P:(DE-2719)9001652
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9002626
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)9002620
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)9001160
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 6
|6 P:(DE-2719)9001214
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)9000882
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 12
|6 P:(DE-2719)2814810
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)2811659
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)2811373
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 15
|6 P:(DE-2719)9001539
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-06
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-01-06
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-06
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-06
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-06
920 1 _ |0 I:(DE-2719)1110007
|k AG Haass
|l Molecular Neurodegeneration
|x 0
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 1
920 1 _ |0 I:(DE-2719)1111016
|k AG Levin
|l Clinical Neurodegeneration
|x 2
920 1 _ |0 I:(DE-2719)1110002
|k AG Höglinger
|l Translational Neurodegeneration
|x 3
980 _ _ |a abstract
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a journal
980 _ _ |a I:(DE-2719)1110007
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)1111016
980 _ _ |a I:(DE-2719)1110002
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21